Document:

Exhibit
      10.2

    

    MEMBERSHIP
      INTEREST EXCHANGE AGREEMENT

     

    This
      Membership Interest Exchange Agreement made this as of the 20th
      day of
      December 2007 by and among between SFH I Acquisition Corp., a Delaware
      corporation, with a principal place of business located at 17395 N. Bay Road
      Suite 102 Sunny Isles, Florida 33160, (the “Company” or “the Corporation”),
      Pharmco, LLC, a Florida limited liability company with a principal place of
      business located at 901 North Miami Beach Blvd., North Miami Beach, Florida
      33162(“Pharmco"), together with each of the members of Pharmco (as hereinafter
      defined).

    

    Recitals:

    

    A. The
      Corporation has offered to issue ten million shares of its common stock, $.0001
      par value (the "Common Stock), to the holders of Membership Interests of Pharmco
      (the "Pharmco Membership Holders") in exchange for their contribution to the
      Corporation of all of the issued and outstanding membership interests of Pharmco
      (the “Pharmco Membership Interests”).

    

    B. The
      respective Boards of Directors of the Corporation and Pharmco have determined
      that, subject to the terms, conditions, agreements, representations and
      warranties set forth herein, the exchange contemplated herein will serve the
      general welfare and advantage of their respective businesses.

    

    C. Subject
      to the terms and conditions set forth herein, the Pharmco Members desire to
      contribute and exchange all of the Pharmco Membership Interests for shares
      of
      Common Stock of the Corporation in the manner hereinafter set forth
      herein.

    

    D. The
      exchange is intended to comply with the requirements of Section 368 of the
      Internal Revenue Code of 1986, as amended, the Treasury Regulations promulgated
      thereunder and the interpretive rulings issued pursuant thereto.

    

    NOW,
      THEREFORE, in consideration of the foregoing recitals, as well as the mutual
      covenants hereinafter set forth, the parties hereto, intending to be legally
      bound, hereby agree as follows:

    

    ARTICLE
      I

    EXCHANGE
      PROVISIONS

    

    1.1  Contribution.

    

    Subject
      to the terms and conditions hereinafter set forth:

     

    (a) Each
      Pharmco Member agrees to contribute, transfer, assign and convey at Closing
      all
      of their Pharmco Membership Interests to the Corporation, together with all
      other rights, claims and interests he or she may have with respect to Pharmco
      or
      its respective assets, and all claims he may have against its officers and
      directors, including, but not limited to, all rights to unpaid dividends and
      all
      claims and causes of action arising from or in connection with the ownership
      of
      Pharmco Membership Interests or its issuance, excluding any right, claim or
      interest of same arising under this Agreement or in connection with the
      transaction contemplated by this Agreement. Each Pharmco Member shall deliver
      to
      the Company at Closing all of his membership certificates representing the
      Pharmco Membership Interests. 

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (b) The
      Corporation agrees to issue to each Pharmco Member the Member’s pro rata portion
      of the total number of Membership Interests to be issued to the Pharmco Members.
      

    

    (c)
      Attached hereto and marked Schedule 1.1 is a list of the Pharmco Members, the
      number of Membership Interests and/or their pro rata share in the outstanding
      Membership Interests each owns as of the date of this Agreement and the number
      of shares of Common Stock each will receive at Closing. 

    

    1.2
      No
      Registration.

    

    (a) Each
      of
      the Pharmco Members acknowledges and agrees that:

    

    (i) The
      Common Stock to be issued to the Pharmco Members (the "Exchanged Corporation
      Stock") is being issued to Pharmco Members without registration under applicable
      federal and state securities laws in reliance upon certain exemptions from
      registration under such securities laws;

    

    (ii) Each
      member has had the opportunity to ask questions of and receive answers from
      the
      Corporation, Pharmco and their respective executive officers concerning their
      businesses and the Exchanged Corporation Stock and all such inquiries have
      been
      completed to his satisfaction;

    

    (iii) Each
      certificate representing shares of the Exchanged Corporation Stock will bear
      a
      legend restricting its transfer, sale, conveyance or hypothecation, unless
      such
      Exchanged Corporation Stock is either registered under applicable securities
      laws or an exemption from such registration is applicable, and provided that
      if
      an exemption from registration is claimed, the Corporation may require an
      opinion of legal counsel that, as a result of such exemption, registration
      under
      the securities laws is not required to transfer, sell, convey or hypothecate
      such Exchanged Corporation Stock;

    

    (iv) Each
      member shall not transfer any Exchanged Corporation Stock except in compliance
      with all applicable securities laws;

    

    (v) Each
      member has a pre-existing personal or business relationship with the Company
      or
      its officers, directors, agents or controlling persons, and has relied, if
      at
      all, on the advice of such persons in electing to participate in the transaction
      herein contemplated and not on any representations of the Corporation other
      than
      those expressly set forth herein, or by reason of his business or financial
      experience could be reasonably assumed to have the capacity to protect his
      own
      interest in connection with the transaction;

    

    (vi) Each
      member is acquiring the Exchanged Corporation Stock for his own account, for
      investment purposes only and not with a view to the sale or distribution
      thereof;

    

    (vii) He
      has
      not received any general solicitation or general advertising regarding the
      acquisition of the Exchanged Corporation Stock; 

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (viii) He
      is
      capable of evaluating the merits and risks of an investment in the Common Stock
      because he is a sophisticated investor by virtue of his prior investments and
      has experience in investments similar in nature to the Common Stock, including
      investments in unlisted and unregistered securities, and has knowledge and
      experience in financial and business matters in general; and 

    

    (ix.) Each
      member agrees and understands that the terms and conditions of this Agreement
      were not negotiated in an arm’s length transaction as the manager of Pharmco is
      also the president of the Company.  

    

    1.6  Closing.
      Consummation of the contemplated transaction shall take place on the date that
      all the conditions set forth herein are satisfied or waived by the appropriate
      parties at the offices of Jeffrey G. Klein, P.A., 2600 North Military Trail,
      Suite 270 Boca Raton, FL 33431 or at another time or place that is mutually
      agreeable to the parties hereto, or on such other date at such other time as
      may
      be mutually agreed upon in writing by the parties hereto (the
      "Closing").

     

    ARTICLE
      II

    THE
      CORPORATION'S REPRESENTATIONS AND WARRANTIES

    

    The
      Corporation hereby makes the following representations and warranties to the
      Pharmco Members and Pharmco, each of which the Corporation represents to be
      true
      and correct on the date hereof and (except as the Corporation may notify Pharmco
      in writing prior to the Closing) shall be deemed made again as of the Closing
      and represented by the Corporation to be true and correct at the time of the
      Closing.

    

    2.1  Organization.
      The
      Corporation is a corporation duly organized, validly existing and in good
      standing under the laws of the State of Delaware. The Corporation has the full
      power and authority to conduct the business in which it will engage upon
      completion of the transaction contemplated herein. Except as set forth in the
      Corporation’s filings with the Securities and Exchange Commission, the
      Corporation does not have any subsidiary or equity interest in any entity.
      Accurate,
      current and complete copies of the Articles of Incorporation and Bylaws of
      the
      Corporation have been filed with the Securities and Exchange Commission and
      are
      available at www.sec.gov.
      

    

    2.2  Stock
      Ownership.
      The
      authorized capital stock of the Corporation consists of one hundred twenty
      million shares of 

    Common
      Stock, consisting of one hundred million shares of Common Stock and twenty
      million shares of Preferred Stock. There are currently ten million shares of
      common stock issued and outstanding. There are no preferred shares outstanding.
      The Company is currently in negotiation for the possible issuance of an
      additional 45 million shares of common stock in connection with a potential
      acquisition. 

    

    All
      the
      issued and outstanding shares of capital stock of the Corporation are duly
      authorized, validly issued, fully paid and nonassessable. Upon tender of the
      Pharmco membership interests in the manner contemplated in Section 1.1 hereof,
      legal and beneficial ownership of the Exchanged Corporation Stock shall be
      transferred to and vested in the Pharmco Members free and clear of all
      encumbrances,except those required by Rule 144 of the Securities Act,and all
      the
      Exchanged Corporation Stock shall be duly authorized, validly issued, fully
      paid
      and nonassessable. There are no outstanding bonds, debentures, notes or other
      indebtedness or other securities of the Corporation having the right to vote
      (or
      convertible into, or exchangeable for, securities having the right to vote)
      on
      any matters on which shareholders of the Corporation may vote. Except as set
      forth above, there are no outstanding securities, options, warrants, calls,
      rights, commitments, agreements, arrangements or undertakings of any kind to
      which the Corporation is a party or by which it is bound obligating the
      Corporation to issue, deliver or sell, or cause to be issued, delivered or
      sold,
      additional shares of capital stock or other equity or voting securities of
      the
      Corporation or obligating the Corporation to issue, grant, extend or enter
      into
      any such security, option, warrant, call, right, commitment, agreement,
      arrangement or undertaking. There are no outstanding contractual obligations,
      commitments, understandings or arrangements of the Corporation to repurchase,
      redeem or otherwise acquire or make any payment in respect of any shares of
      capital stock of the Corporation.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    2.3  Authority
      and Approval of Agreement.

    

    (a) The
      execution and delivery of this Agreement by the Corporation and the performance
      of all the Corporation's obligations hereunder have been duly authorized and
      approved by all requisite corporate action on the part of the Corporation
      pursuant to applicable law. The Corporation has the power and authority to
      execute and deliver this Agreement and to perform all its obligations
      hereunder.

    

    (b) This
      Agreement and any other documents, instruments and agreements executed by the
      Corporation in connection herewith constitute the valid and legally binding
      agreements of the Corporation, enforceable against the Corporation in accordance
      with their terms, except that (i) enforceability may be limited by applicable
      bankruptcy, insolvency, reorganization, moratorium or similar laws of general
      application affecting the enforcement of the rights and remedies of creditors;
      and (ii) the availability of equitable remedies may be limited by equitable
      principles.

    

    
      
        2.4 
          No
          Violations.

      

    

    

    Neither
      the execution, delivery nor performance of this Agreement or any other
      documents, instruments or agreements executed by the Corporation in connection
      herewith, nor the consummation of the transactions contemplated hereby: (i)
      constitutes a violation of or default under (either immediately, upon notice
      or
      upon lapse of time) the Articles of Incorporation or Bylaws of the Corporation,
      any provision of any contract to which the Corporation may be bound, any
      judgment or any law; or (ii) will or could result in the creation or imposition
      of any encumbrance upon, or give to any third person any interest in or right
      to, the Exchanged Corporation Stock or any other capital stock of the
      Corporation; or (iii) will or could result in the loss or adverse modification
      of, or the imposition of any fine or penalty with respect to, any license,
      permit or franchise granted or issued to, or otherwise held by or for the use
      of, the Corporation.

    

    2.5  Financial
      Statements.
      The
      financial statements as filed by the Corporation with the Securities and
      Exchange Commission set forth the financial condition of the Company. The
      Financial Statements are true, correct and complete, were prepared in accordance
      with generally accepted accounting principles consistently applied throughout
      the periods indicated, and accurately reflect the Corporation's financial
      condition and the results of the Corporation's operations for the periods and
      as
      of the dates which they purport to cover.

    

    2.6  Conduct
      Since Date of Balance Sheet.
      Except
      as disclosed in Schedule
      2.6
      hereto
      or as otherwise set forth herein none of the following has occurred since the
      date of the Balance Sheet:

    

    (a) Any
      material adverse change in the financial condition, obligations, capitalization,
      business, prospects or operations of the Corporation, nor are there any
      circumstances known to the Corporation which might result in such a material
      adverse change or such an effect;

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (b) Any
      settlement or other resolution of any dispute or proceeding other than in the
      ordinary course of business;

    

    (c) Any
      cancellation by the Corporation, without payment in full, of any obligation
      to
      the Corporation of any shareholder, director, officer or employee of the
      Corporation (or any member of their respective families), or any entity in
      which
      any shareholder, director or officer of the Corporation (or any member of their
      respective families) has any direct or indirect interests;

    

    (d) Any
      payment, discharge or satisfaction of any obligation or judgment, other than
      in
      the ordinary course of business; or

    

    (e) Any
      agreement obligating the Corporation to do or take any of the actions referred
      to in this Section 2.7 outside the ordinary course of business.

    

    2.7  Labor
      Matters.
      The
      Corporation is not and has never been a party to: (i) any profit sharing,
      pension, retirement, deferred compensation, bonus, stock option, stock purchase,
      retainer, consulting, health, welfare or incentive plan or agreement or other
      employee benefit plan, whether legally binding or not; or (ii) any plan
      providing for "fringe benefits" to its employees, including, but not limited
      to,
      vacation, disability, sick leave, Pharmco, hospitalization and life insurance
      and other insurance plans, or related benefits; or (iii) any employment
      agreement other than with Byron Webb. No former employee of the Corporation
      has
      any claim against the Corporation (whether under federal or state law, any
      employment agreement or otherwise) on account of or for: (i) overtime pay;
      (ii)
      wages or salary for any period; (iii) vacation, time-off or pay in lieu of
      vacation or time-off; or (iv) any violation of any statute, ordinance or
      regulation relating to minimum wages or maximum hours of work. No person or
      party (including, but not limited to, governmental agencies of any kind) has
      any
      claim or basis for any action or proceeding against the Corporation arising
      out
      of any statute, ordinance or regulation relating to discrimination in employment
      or to employment practices or occupational safety and health
      standards.

    

    2.8  Environmental
      Matters.
      The
      Corporation has not generated any hazardous wastes or engaged in activities
      which are or could be interpreted to be potential violations of laws or judicial
      decrees in any manner regulating the generation or disposal of hazardous waste.
      There are no on-site or off-site locations where the Corporation has stored,
      disposed or arranged for the disposal of chemicals, pollutants, contaminants,
      wastes, toxic substances, petroleum or petroleum products; there are no
      underground storage tanks located on property owned or leased by the
      Corporation, and no polychlorinated biphenyls are used or stored at any property
      owned or leased by the Corporation.

    

    2.9  Books
      and Records.
      The
      Corporation's books and records are and have been properly prepared and
      maintained in form and substance adequate for preparing audited financial
      statements in accordance with generally accepted accounting principles, and
      fairly and accurately reflect all of the Corporation's assets, obligations
      and
      accruals, and all transactions (normally reflected in books and records in
      accordance with generally accepted accounting principles) to which the
      Corporation is or was a party or by which the Corporation or any of its assets
      are or were affected.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    2.10  Taxes.
      Except
      as otherwise disclosed in this Agreement, or any applicable SEC filings, all
      taxes due, owing and payable by the Corporation have been fully paid. The
      amounts set up as provision for taxes on the Balance Sheet are sufficient for
      the payment of all accrued and unpaid taxes of the Corporation, whether or
      not
      disputed. The amount set up as provision for taxes on the Corporation's books
      and records for the current fiscal year through the Closing shall be sufficient
      for the payment of all accrued and unpaid taxes of the Corporation, whether
      or
      not disputed, for such period. No claim for any tax due from or assessed against
      the Corporation is being contested by the Corporation. None of the Corporation's
      tax returns or reports has been audited by the Internal Revenue Service or
      any
      state or local tax authority, and the Corporation has not received any notice
      of
      deficiency or other adjustment from the Internal Revenue Service or any state
      or
      local tax authority. There are no agreements, waivers or other arrangements
      providing an extension of time with respect to the assessment of any tax against
      the Corporation, nor are there any tax proceedings now pending or threatened
      against the Corporation. No state of facts exists or has existed, nor has any
      event occurred, which would constitute grounds for the assessment of any further
      tax against the Corporation.

    

    2.11  Litigation.
      The
      Corporation is not a party to, the subject of, or threatened with any litigation
      nor, to the best of the Corporation's knowledge, is there any basis for any
      litigation. The Corporation is not contemplating the institution of any
      litigation.

    

    2.12  Other
      Liabilities.
      No
      claim of breach of contract, tort, product liability or other claim, contingent
      or otherwise, has been asserted or threatened against the Corporation nor,
      to
      the best of the Corporation's knowledge, is capable of being asserted by any
      employee, creditor, claimant or other person against the Corporation. No state
      of facts exists or has existed, nor has any event occurred, which could give
      rise to the assertion of any such claim by any person.

    

    2.13  Judgments.
      There
      is no outstanding judgment against the Corporation. There is no health or safety
      problem involving or affecting the Corporation. There are no open workers
      compensation claims against the Corporation, or any other obligation, fact
      or
      circumstance which would give rise to any right of indemnification on the part
      of any current or former shareholder, director, officer, employee or agent
      of
      the Corporation, or any heir or personal representative thereof, against the
      Corporation or any successor to the businesses of the Corporation.

    

    2.14  Improper
      Payments.
      Neither
      the Corporation, nor any of its current or former shareholders, directors,
      officers or employees or agents, nor any person acting on behalf of the
      Corporation, has, directly or indirectly, made any bribe, kickback or other
      payment of a similar or comparable nature, whether lawful or not, to any person,
      public or private, regardless of form, whether in money, property or services,
      to obtain favorable treatment for business secured or special concessions
      already obtained. No funds or assets of the Corporation were donated, lent
      or
      made available directly or indirectly for the benefit of, or for the purpose
      of
      supporting or opposing, any government or subdivision thereof, political party,
      candidate or committee, either domestic or foreign. The Corporation has not
      maintained and does not maintain a bank account, or any other account of any
      kind, whether domestic or foreign, which account was not or is not reflected
      in
      the Corporation's books and records, or which account was not listed, titled
      or
      identified in the name of the Corporation.

    

    2.15  Full
      Disclosure.
      All the
      representations and warranties made by the Corporation herein or in any
      Schedule, and all of the statements, documents or other information pertaining
      to the transaction contemplated herein made or given by the Corporation, its
      agents or representatives, are complete and accurate, and do not omit any
      information required to make the statements and information provided, in light
      of the transaction contemplated herein, non-misleading, accurate and
      meaningful.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
ARTICLE
      III

    PHARMCO'S
      REPRESENTATIONS AND WARRANTIES

    

    Pharmco
      hereby makes the following representations and warranties to the Corporation,
      each of which Pharmco represents to be true and correct on the date hereof
      and
      (except as Pharmco may notify the Corporation in writing prior to the Closing)
      shall be deemed made again as of the Closing and represented by Pharmco to
      be
      true and correct at the time of the Closing.

    

    3.1  Organization.
      Pharmco
      is a limited liability corporation duly organized, validly existing and in
      good
      standing under the laws of the State of Florida and is not required to be
      qualified or licensed as a foreign corporation in any other jurisdiction.
      Pharmco has the full power and authority to own all its assets and to conduct
      its business as and where its business is presently conducted. Accurate, current
      and complete copies of the Articles of Incorporation and Bylaws of Pharmco
      are
      to be attached hereto as Schedule
      3.1.
      Pharmco
      has no subsidiaries or equity interest in any entity.

    

    3.2  Membership
      Ownership.
      Schedule 1.1 sets forth the owners of all of the issued and outstanding
      Membership Interests of Pharmco as of the date hereof. All the issued and
      outstanding membership interests are duly authorized, validly issued, fully
      paid
      and nonassessable. There are no outstanding bonds, debentures, notes or other
      indebtedness or other securities of Pharmco having the right to vote (or
      convertible into, or exchangeable for, securities having the right to vote)
      on
      any matters on which members of Pharmco may vote. Except as set forth above,
      there are no outstanding securities, options, warrants, calls, rights,
      commitments, agreements, arrangements or undertakings of any kind to which
      Pharmco is a party or by which it is bound obligating Pharmco to issue, deliver
      or sell, or cause to be issued, delivered or sold, additional membership
      interests or other equity or voting securities of Pharmco or obligating Pharmco
      to issue, grant, extend or enter into any such security, option, warrant, call,
      right, commitment, agreement, arrangement or undertaking. There are no
      outstanding contractual obligations, commitments, understandings or arrangements
      of Pharmco to repurchase, redeem or otherwise acquire or make any payment in
      respect of any membership interests. Notwithstanding the foregoing, if prior
      to
      closing, Pharmco shall issue additional membership interests, Pharmco shall
      so
      advise the Corporation. However, the total number of shares of the Exchanged
      Corporation Stock to be delivered to the Pharmco Members shall not be adjusted
      as a result of any increase or decrease in the number of membership interests.
      

     

    No
      additional Membership Interests will be issued following execution of this
      Agreement unless terminated as provided for herein.

    

    3.3  Authority
      and Approval of Agreement.

    

    (a) The
      execution and delivery of this Agreement by Pharmco and the performance of
      all
      Pharmco's obligations hereunder have been duly authorized and approved by all
      requisite corporate action on the part of Pharmco pursuant to applicable law.
      Pharmco has the power and authority to execute and deliver this Agreement and
      to
      perform all its obligations hereunder.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (b) This
      Agreement and each of the other documents, instruments and agreements executed
      by Pharmco in connection herewith constitute the valid and legally binding
      agreements of Pharmco, enforceable against Pharmco in accordance with their
      terms, except that: (i) enforceability may be limited by applicable bankruptcy,
      insolvency, reorganization, moratorium or similar laws of general application
      affecting the enforcement of the rights and remedies of creditors; and (ii)
      the
      availability of equitable remedies may be limited by equitable
      principles.

    

    3.4  No
      Violations.
      Neither
      the execution, delivery nor performance of this Agreement or any other
      documents, instruments or agreements executed by Pharmco in connection herewith,
      nor the consummation of the transactions contemplated hereby: (i) constitutes
      a
      violation of or default under (either immediately, upon notice or upon lapse
      of
      time) the Articles of Organization or Bylaws of Pharmco, any provision of any
      Contract to which Pharmco or its assets may be bound, any judgment to which
      Pharmco is bound or any law applicable to Pharmco; or (ii) result in the
      creation or imposition of any encumbrance upon, or give to any third person
      any
      interest in or right to, any other capital stock of Pharmco or any of the assets
      of Pharmco; or (iii) result in the loss or adverse modification of, or the
      imposition of any fine or penalty with respect to, any license, permit or
      franchise granted or issued to, or otherwise held by or for the use of,
      Pharmco.

    

    3.5  Consents.
      Subject
      only to the consents of the Pharmco members, the execution, delivery and
      performance by Pharmco of this Agreement and the consummation by Pharmco of
      the
      transactions contemplated hereby do not require any consent that has not been
      received prior to the date hereof.

    

    3.6  Pharmco
      Financial Statements.
      Pharmco
      shall provide the Company with audited financial statements as required by
      the
      Securities and Exchange Commission as a condition precedent to closing.

    

    3.7  Contracts.
      Schedule
      3.8
      will set
      forth an accurate, current and complete list and description of each material
      Contract (other than this Agreement) to which Pharmco is a party or by which
      Pharmco or any of its assets are bound. An accurate, current and complete copy
      of each material Contract described in Schedule
      3.8
      hereto
      shall be furnished to the Corporation prior to Closing.

    

    3.8  Labor
      Matters.
      Pharmco
      is not and has never been a party to: (i) any profit sharing, pension,
      retirement, deferred compensation, bonus, stock option, stock purchase,
      retainer, consulting, health, welfare or incentive plan or agreement or other
      employee benefit plan, whether legally binding or not; or (ii) any plan
      providing for "fringe benefits" to its employees, including, but not limited
      to,
      vacation, disability, sick leave, Pharmco, hospitalization and life insurance
      and other insurance plans, or related benefits; or (iii) any employment
      agreement. No former employee of Pharmco has any claim against Pharmco (whether
      under federal or state law, any employment agreement or otherwise) on account
      of
      or for: (i) overtime pay; (ii) wages or salary for any period; (iii) vacation,
      time-off or pay in lieu of vacation or time-off; or (iv) any violation of any
      statute, ordinance or regulation relating to minimum wages or maximum hours
      of
      work. No person or party (including, but not limited to, governmental agencies
      of any kind) has any claim or basis for any action or proceeding against Pharmco
      arising out of any statute, ordinance or regulation relating to discrimination
      in employment or to employment practices or occupational safety and health
      standards.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    3.9  Environmental
      Matters.
      Except
      as set forth in Schedule
      3.12
      Pharmco
      has not generated any hazardous wastes or engaged in activities which are or
      could be interpreted to be potential violations of laws or judicial decrees
      in
      any manner regulating the generation or disposal of hazardous waste. There
      are
      no on-site or off-site locations where Pharmco has stored, disposed or arranged
      for the disposal of chemicals, pollutants, contaminants, wastes, toxic
      substances, petroleum or petroleum products; there are no underground storage
      tanks located on property owned or leased by Pharmco.

    

    3.10  Books
      and Records.
      Pharmco's books and records are and have been properly prepared and maintained
      in form and substance adequate for preparing audited financial statements in
      accordance with generally accepted accounting principles, and fairly and
      accurately reflect all of Pharmco's assets, obligations and accruals, and all
      transactions (normally reflected in books and records in accordance with
      generally accepted accounting principles) to which Pharmco is or was a party
      or
      by which Pharmco or any of its assets are or were affected.

    

    3.11  Taxes.
      Except
      as otherwise disclosed in this Agreement, all taxes due, owing and payable
      by
      Pharmco have been fully paid. The amounts set up as provision for taxes on
      the
      Pharmco Balance Sheet are sufficient for the payment of all accrued and unpaid
      taxes of Pharmco, whether or not disputed. The amount set up as provision for
      taxes on Pharmco's books and records for the current fiscal year through the
      Closing shall be sufficient for the payment of all accrued and unpaid taxes
      of
      Pharmco, whether or not disputed, for such period. No claim for any tax due
      from
      or assessed against Pharmco is being contested by Pharmco. None of Pharmco's
      tax
      returns or reports has been audited by the Internal Revenue Service or any
      state
      or local tax authority, and Pharmco has not received any notice of deficiency
      or
      other adjustment from the Internal Revenue Service or any state or local tax
      authority. There are no agreements, waivers or other arrangements providing
      an
      extension of time with respect to the assessment of any tax against Pharmco,
      nor
      are there any tax proceedings now pending or threatened against Pharmco. No
      state of facts exists or has existed, nor has any event occurred, which would
      constitute grounds for the assessment of any further tax against Pharmco.

    

    3.12  Litigation.
      Except
      as set forth in Schedule 3.12, Pharmco is not a party to, the subject of, or
      threatened with any litigation nor, to the best of Pharmco's knowledge, is
      there
      any basis for any litigation. Pharmco is not contemplating the institution
      of
      any litigation.

    

    3.13  Other
      Liabilities.
      No
      claim of breach of contract, tort, product liability or other claim (whether
      arising from Pharmco's business operations or otherwise), contingent or
      otherwise, has been asserted or threatened against Pharmco nor, to the best
      of
      Pharmco's knowledge, is capable of being asserted by any employee, creditor,
      claimant or other person against Pharmco. No state of facts exists or has
      existed, nor has any event occurred, which could give rise to the assertion
      of
      any such claim by any person.

    

    3.14  Consents.
      The
      execution, delivery and performance by Pharmco of this Agreement and the
      consummation by Pharmco of the transactions contemplated hereby do not require
      any consent that has not been received prior to the date hereof.

    

    3.15  Judgments.
      There
      is no outstanding judgment against Pharmco. There is no health or safety problem
      involving or affecting Pharmco. There are no open workers compensation claims
      against Pharmco, or any other obligation, fact or circumstance which would
      give
      rise to any right of indemnification on the part of any current or former
      shareholder, partner, director, officer, employee or agent of Pharmco, or any
      heir or personal representative thereof, against Pharmco or any successor to
      the
      business of Pharmco.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    3.16  Compliance
      with Laws.
      Pharmco
      and its business are in full compliance with all laws.

    

    3.17  Improper
      Payments.
      Neither
      Pharmco, nor any of its current or former shareholders, partners, directors,
      officers or employees or agents, nor any person acting on behalf of Pharmco,
      has, directly or indirectly, made any bribe, kickback or other payment of a
      similar or comparable nature, whether lawful or not, to any person, public
      or
      private, regardless of form, whether in money, property or services, to obtain
      favorable treatment for business secured or special concessions already
      obtained. No funds or assets of Pharmco were donated, lent or made available
      directly or indirectly for the benefit of, or for the purpose of supporting
      or
      opposing, any government or subdivision thereof, political party, candidate
      or
      committee, either domestic or foreign. Pharmco has not maintained and does
      not
      maintain a bank account, or any other account of any kind, whether domestic
      or
      foreign, which account was not or is not reflected in the Pharmco corporate
      books and records, or which account was not listed, titled or identified in
      the
      name of Pharmco.

    

    3.18  Full
      Disclosure.
      All the
      representations and warranties made by Pharmco herein or in any Schedule hereto,
      and all of the statements, documents or other information pertaining to the
      transaction contemplated herein made or given by Pharmco, its agents or
      representatives are complete and accurate, and do not omit any information
      required to make the statements and information provided, in light of the
      transaction contemplated herein, non-misleading, accurate and
      meaningful.

    

    ARTICLE
      IV

    PHARMCO
      MEMBERSHIP INTERESTS' REPRESENTATIONS,

    WARRANTIES
      AND AGREEMENTS

    

    Each
      Pharmco Member hereby makes the following representations and warranties to
      the
      Corporation, each of which such Pharmco Member represents to be true and correct
      on the date hereof and (except as such Pharmco Member may notify the Corporation
      in writing prior to the Closing) shall be deemed made again as of the Closing
      and represented by such Pharmco Member to be true and correct at the time of
      the
      Closing.

    

    4.1  Title
      to Membership Interest.
      He is
      the sole owner, legally and beneficially, of the Pharmco Membership Interest
      stock set forth on Exhibit Schedule
      1.1
      hereto
      opposite his name, the consideration payable by him therefore has been paid
      and
      such membership interest is fully paid and nonassessable and free and clear
      of
      all encumbrances of every kind. He has full legal right, power and authority
      to
      enter into this Agreement and to sell, assign and transfer such membership
      interest to the Corporation. The delivery to the Corporation of such membership
      interest pursuant to the provisions of this Agreement will transfer to the
      Corporation valid title thereto, free and clear of all encumbrances of every
      kind except any created by the Corporation. The Pharmco membership interest
      represents his entire interest in Pharmco. He has no other rights, claims or
      interest to, against or in Pharmco, or its officers and directors.

    

    4.2  Enforceability.
      This
      Agreement and each of the other documents, instruments and agreements executed
      by him in connection herewith constitute the valid and legally binding
      agreements of him, enforceable against him in accordance with their terms,
      except that: (i) enforceability may be limited by applicable bankruptcy,
      insolvency, reorganization, moratorium or similar laws of general application
      affecting the enforcement of the rights and remedies of creditors; and (ii)
      the
      availability of equitable remedies may be limited by equitable
      principles.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    4.3  Brokerage
      Fees.
      There
      is no person acting on behalf of him who is entitled to or has any claim for
      any
      brokerage or finder's fee or commission in connection with the execution of
      this
      Agreement or the consummation of the transactions contemplated
      hereby.

     

    ARTICLE
      V

    INTERPRETATION
      AND SURVIVAL OF

    REPRESENTATIONS
      AND WARRANTIES

    

    5.1  Interpretation.
      Each
      warranty and representation made by a party in this Agreement or pursuant hereto
      is independent of all other warranties and representations made by the same
      party in this Agreement or pursuant hereto (whether or not covering identical,
      related or similar matters) and must be independently and separately satisfied.
      Exceptions or qualifications to any such warranty or representation shall not
      be
      construed as exceptions or qualifications to any other warranty or
      representation.

    

    5.2  Survival.
      All
      representations and warranties made in this Agreement or pursuant hereto shall
      survive the date hereof, the Closing, the consummation of the transaction
      contemplated hereby and any investigation.

     

    ARTICLE
      VI

    OBLIGATIONS
      PRIOR TO CLOSING

    

    6.1  Conduct
      of the Corporation and Pharmco Pending Closing.
      During
      the period from the date hereof until the Closing Date, except with the express
      prior written consent of the other party, the Corporation and Pharmco hereby
      covenant and agree that:

    

    (a) each
      shall maintain its existence in good standing in the state of its incorporation
      and each other jurisdiction where it is required to be licensed or qualified
      as
      a foreign corporation, and shall not alter or amend its Articles of
      Incorporation or Bylaws;

    

    (b) each
      shall duly and timely file all returns and reports required by any law to be
      filed by it, shall promptly pay when due all taxes assessed against it or any
      of
      its assets, and shall conform to and fully comply with all the laws pertaining
      to its assets or the conduct of its business; and

    

    (c) each
      shall not take any action, or enter into any agreement that would cause a breach
      of any of the representations and warranties made herein by the Corporation
      or
      Pharmco, as applicable.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    ARTICLE
      VII

    CONDITIONS
      PRECEDENT TO PHARMCO'S AND THE

    PHARMCO
      MEMBERSHIP INTERESTS' OBLIGATIONS

    

    Notwithstanding
      the execution and delivery of this Agreement or the performance of any part
      hereof, Pharmco's and each of the Pharmco Membership Interests' respective
      obligations to consummate the transaction contemplated by this Agreement shall
      be subject to the satisfaction of each of the conditions set forth in this
      Article VII, except to the extent that such satisfaction is waived in writing
      by
      Pharmco and a majority in interest of the Pharmco Membership
      Interests.

    

    7.1  Representations
      and Warranties of the Corporation.
       All
      representations and warranties made by the Corporation in this Agreement and
      the
      Schedules hereto shall be true and correct in all respects on the date hereof,
      and shall be true and correct in all respects at the time of the Closing as
      though such representations were again made, without exception or deviation,
      at
      the time of the Closing.

    

    7.2  Performance
      of this Agreement.
      The
      Corporation shall have duly performed or complied with all the obligations
      under
      this Agreement to be performed or complied with by the Corporation on or prior
      to the Closing.

    

    7.3  Absence
      of Litigation.
      No
      litigation shall have been instituted on or before the time of the Closing
      by
      any person, the result of which did or could prevent or make illegal the
      consummation of the transaction contemplated by this Agreement, or which had
      or
      could have a material adverse effect on the business of the
      Corporation.

     

    ARTICLE
      VIII

    CONDITIONS
      PRECEDENT TO THE

    CORPORATION'S
      OBLIGATIONS

    

    Notwithstanding
      the execution and delivery of this Agreement or the performance of any part
      hereof, the Corporation's obligations to consummate the transaction contemplated
      by this Agreement shall be subject to the satisfaction of each of the conditions
      set forth in this Article VIII, except to the extent that such satisfaction
      is
      waived by the Corporation in writing.

    

    8.1  Representations
      and Warranties of Pharmco and the Pharmco Members.
      All
      representations and warranties made by Pharmco and the Pharmco Members contained
      in this Agreement and the Schedules hereto shall be true and correct in all
      respects on the date hereof, and shall be true and correct in all respects
      at
      the time of the Closing as though such representations were again made, without
      exception or deviation, at the time of the Closing.

    

    8.2  Performance
      of this Agreement.
      The
      owners of 100% of the issued and outstanding membership interests of Pharmco
      shall have executed this Agreement. Pharmco and the Pharmco Members shall have
      duly performed or complied with all of the covenants and obligations under
      this
      Agreement to be performed or complied with by them on or prior to the
      Closing.

    

    8.3  Absence
      of Litigation.
      Except
      as otherwise disclosed in this agreement, no litigation has been instituted
      on
      or before the time of the Closing by any person, the result of which did or
      could prevent or make illegal the consummation of the transaction contemplated
      by this Agreement.

    

    8.4  Deliveries
      of Audited Financial Statements.
      Closing
      shall be contingent upon delivery of the Pharmco audited financial statements
      in
      accordance with applicable rules and regulations. If said statements have not
      been delivered on or before March 31, 2008, the Company, in its sole and
      absolute discretion may terminate this Agreement.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    8.5  Schedules.
      Pharmco
      shall have provided to the Corporation all referenced schedules.

    

    ARTICLE
      IX

    OBLIGATIONS
      AT CLOSING

    

    9.1  Obligations
      of the Corporation to Pharmco and the Pharmco Members at Closing.
      The
      Corporation hereby covenants and agrees to deliver or cause to be delivered
      to
      Pharmco and Pharmco Members at the Closing the following:

    

    (a) Duly
      issued certificates (legended as provided in Section 1.5(a)(iii) hereof)
      representing all the Exchanged Corporation Stock, together with any documentary
      stamps required in connection with such transfer and such other appropriate
      documents and instruments of transfer as Pharmco may reasonably
      request.

    

    (b) An
      Active
      Status Certificate for the Corporation, dated no earlier than ten (10) days
      before the Closing, from the State of Delaware. 

    

    (c) A
      copy of
      the resolutions adopted by the Board of Directors of the Corporation, certified
      by its corporate secretary, which resolutions authorize it to execute, deliver
      and perform this Agreement and consummate the transactions contemplated
      hereby.

    

    9.2  Pharmco's
      Obligations to the Corporation.
      Pharmco
      agrees to deliver or cause to be delivered to the Corporation at the Closing
      the
      following:

    

    (a) A
      Good
      Standing Certificate for Pharmco dated no earlier than ten (10) days before
      the
      Closing, from the State of Florida.

    

    (b) A
      copy of
      the resolutions adopted by the Board of Directors of Pharmco, certified by
      its
      corporate secretary, which resolutions authorize it to execute, deliver and
      perform this Agreement and consummate the transactions contemplated
      hereby.

    

    (c) All
      outstanding Pharmco Membership Interests to be exchanged for the Exchanged
      Corporation Stock free and clear of all encumbrances. 

    

    9.3  Pharmco
      Members’ Obligations to the Corporation at Closing.
      Each
      Pharmco Member hereby covenants and agrees to deliver to the Corporation at
      the
      Closing the following:

    

    (a) If
      not
      previously delivered to the Corporation, all his Pharmco Membership Interests,
      free and clear of all encumbrances, together with all certificates evidencing
      same and stock powers therefore, in a form acceptable to the Corporation, duly
      executed in blank.

    

    (b) Such
      other documents and instruments as counsel to the Corporation may reasonably
      request.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    ARTICLE
      X

    TERMINATION

    

    10.1  Termination
      on Default.
      If,
      prior to the Closing, a party hereto shall materially breach or default in
      the
      full and timely performance and satisfaction of any of its representations
      and
      warranties or obligations under this Agreement, and such breach or default
      is
      not cured on or before the fifth (5th) day after the date notice is given by
      the
      non-defaulting party to the defaulting party specifying the nature of such
      breach or default (or at or before the time of the Closing if sooner), then
      the
      non-defaulting party may terminate this Agreement immediately upon notice to
      the
      defaulting party; provided, however, that no Pharmco Membership may terminate
      this Agreement.

    

    10.2  Termination
      at Closing.
      If any
      of the conditions set forth in this Agreement are not satisfied at or before
      the
      time of the Closing, then either party may terminate this Agreement upon notice
      to the other. 

    

      
      ARTICLE XII

    MISCELLANEOUS

    

    11.1  Notices.
      All
      notices, requests, demands and other communications hereunder shall be deemed
      to
      have been duly given if the same shall be in writing and shall be delivered
      personally or sent by registered or certified mail, postage prepaid.

    

    11.2  Entire
      Agreement.
      This
      Agreement, including the Schedules attached hereto and the documents delivered
      pursuant hereto, sets forth all the promises, covenants, agreements, conditions
      and understandings among the parties hereto with respect to the subject matter
      hereof, and supersedes all prior and contemporaneous agreements, understandings,
      inducements or conditions, expressed or implied, oral or written, except as
      herein contained. No changes of or modifications or additions to this Agreement
      shall be valid unless same shall be in writing and signed by the parties
      hereto.

    

    11.3  Binding
      Effect; Assignment.
      This
      Agreement shall be binding upon the parties hereto, their beneficiaries, heirs
      and administrators. No party may assign or transfer its interests herein, or
      delegate its duties hereunder, without the written consent of the other
      parties.

    

    11.4  Amendment.
      The
      parties hereby irrevocably agree that no attempted amendment, modification
      or
      change (collectively, "Amendment") of this Agreement shall be valid and
      effective, unless the parties shall unanimously agree in writing to such
      Amendment.

    

    11.5  No
      Waiver.
      No
      waiver of any provision of this Agreement shall be effective unless it is in
      writing and signed by the party against whom it is asserted, and any such
      written waiver shall only be applicable to the specific instance to which it
      relates and shall not be deemed to be a continuing or future
      waiver.

    

    11.6  Gender
      and Use of Singular and Plural.
      All
      pronouns shall be deemed to refer to the masculine, feminine, neuter, singular
      or plural, as the identity of the party or parties or their personal
      representatives, successors and assigns may require.

    

    11.7  Counterparts.
      This
      Agreement and any Amendments may be executed in one or more counterparts, each
      of which shall be deemed an original and all of which together shall constitute
      one and the same instrument.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    11.8  Headings.
      The
      article and section headings contained in this Agreement are inserted for
      convenience only and shall not affect in any way the meaning or interpretation
      of the Agreement.

    

    11.9  Governing
      Law.
      This
      Agreement shall be construed in accordance with the laws of the State of
      Florida.

    

    11.10
      Further
      Assurances.
      The
      parties hereto shall execute and deliver such further instruments and do such
      further acts and things as may be reasonably required to carry out the intent
      and purposes of this Agreement.

    

    11.11
      Litigation.
      If any
      party hereto is required to engage in litigation or arbitration against any
      other party hereto, either as plaintiff or as defendant, in order to enforce
      or
      defend any of its or his rights under this Agreement, and such litigation
      results in a final judgment in favor of such party (the "Prevailing Party"),
      then the party or parties against whom said final judgment is obtained shall
      reimburse the Prevailing Party for all direct, indirect or incidental expenses
      incurred by the Prevailing Party in so enforcing or defending its or his rights
      hereunder, including, but not limited to, all attorneys' fees, paralegals'
      fees,
      court costs and other expenses incurred throughout all negotiations, trials
      or
      appeals undertaken in order to enforce the Prevailing Party's rights
      hereunder.

    

    11.12
      Confidentiality.
      Except
      for discussions of the transactions contemplated by this Agreement among the
      parties hereto and their respective representatives and counsel participating
      in
      this transaction, and except as may be required of the Corporation pursuant
      to
      federal securities laws, each party hereto shall, unless all other parties
      hereto shall otherwise agree, keep confidential and not, directly or indirectly,
      disclose to any person the existence of this Agreement, the transaction
      contemplated by this Agreement or any of the terms thereof, or the fact that
      the
      Corporation and Pharmco have entered into discussions or negotiations for any
      purpose whatsoever, and each party hereto shall use its good faith efforts
      to
      cause its employees, agents, officers, directors and representatives to abide
      by
      the foregoing restrictions on disclosure.

    

    WAIVER
      OF CONFLICT: YOU WIL BE EXECUTING A LEGALLY BINDING AGREEMENT. THIS AGREEMENT
      HAS BEEN PREPARED BY JEFFREY G. KLEIN, ATTORNEY, AS COUNSEL FOR SFH I
      ACQUISITION CORP. EACH SIGNATORY TO THIS AGREEMENT HAS BEEN URGED TO SEEK
      INDEPENDENT COUNSEL WITH RESPECT TO THE EXECUTION OF THIS AGREEMENT AND THE
      CONSEQUENCES TO EACH INDIVIDUAL OR MEMBER AS A RESULT OF EXECUTING THIS
      AGREEMENT. PRIOR TO EXECUTION OF THIS AGREEMENT, EACH PARTY HAS HAD THE
      OPPORTUNITY TO DISCUSS THIS AGREEMENT WITH INDEPENDENT COUNSEL. BY EXECUTION
      OF
      THIS AGREEMENT, EACH SIGNATORY HERETO WAIVES ANY POTENTIAL CONFLICT OF
      INTEREST.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    IN
      WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
      as
      of the date and year set forth above.

     

    
      	 	 	 
	 	
              SFH
                I ACQUISITION CORP.

            
	 
 	 
 	 
 
	
            	By:  	
            
	 	
              

              Name:
                Armen Karapetyan

            
	 	
              Title:
                President

            

    

    
      	 	 	 
	 	
              PHARMCO,
                LLC

            
	 
 	 
 	 
 
	
            	By:  	
            
	 	
              

              Name:
                Avraham Friedman

            
	 	
              Title:
                MANAGER

            

    

    
      	 	 	 
	 	
              PHARMCO
                LLC MEMBERS

            
	 
 	  
 
	
            	
              

              Armen
                Karapetyan

            
	 	 
	 	 
	 	
              
                

              

              Avraham
                Friedman

            
	 	 
	 	 
	 	
              

              Andy
                Subachan(4)(1)
      Certificate of Designation of the Series A Convertible Preferred

    

    CERTIFICATE
      OF DESIGNATIONS, POWERS

    PREFERENCES
      AND RIGHTS OF SERIES A CONVERTIBLE

    PREFERRED
      STOCK

    

    -OF-

    

    MASON
      HILL HOLDINGS, INC.

    a
      Delaware corporation

    [Now,
      Attitude Drinks Incorporated]

    

    Pursuant
      to Section 151 of the General Corporation Law of the State of Delaware, the
      undersigned DOES HEREBY CERTIFY that the following resolution was duly adopted
      by the Board of Directors (the “Board of Directors”) of Mason Hill Holdings,
      Inc., a Delaware corporation (the “Corporation”), by a written consent to action
      dated May 26, 2006:

    

    RESOLVED,
      that there be, and hereby is, created out of the class of 20,000,000 shares
      of
      serial preferred stock of the Corporation, par value $.001 per share, a series
      of preferred stock (the “Series A”) with the following designations, powers,
      preferences and relative, participating, optional or other special rights,
      qualifications, limitations or restrictions (this instrument hereinafter
      referred to as the “Designation”):

    

    
      	
              1.

            	
              DEFINITIONS

            

    

    

    Common
      Stock
      . The
      term “Common Stock” shall mean all shares now or hereafter authorized of any
      class of Common Stock of the Company and any other stock of the Company,
      howsoever designated, authorized after the Issue Date, which has the right
      (subject always to prior rights of any class or series of Preferred Stock)
      to
      participate in the distribution of the assets and earnings of the Company
      without limit as to per share amount.

    

    Issue
      Date
      . The
      term “Issue Date” shall mean the date that shares of Series A are first issued
      by the Company.

    

    Junior
      Stock
      . The
      term “Junior Stock” shall mean, for purposes of these resolutions, any class or
      series of stock of the Company authorized after the Issue Date not entitled
      to
      receive any dividends in any dividend period unless any dividends required
      to
      have been paid or declared and set apart for payment on the Series A shall
      have
      been so paid or declared and set apart for payment and, for purposes of these
      resolutions, shall mean Common Stock and any other class or series of stock
      of
      the Company authorized after the Issue Date not entitled to receive any assets
      upon liquidation, dissolution or winding up of the affairs of the Company until
      the Series A shall have received the entire amount to which such stock is
      entitled upon such liquidation, dissolution or winding up.

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Parity
      Stock
      . The
      term “Parity Stock” shall mean, for purposes of these resolutions the Common
      Stock and any other class or series of stock of the Company authorized after
      the
      Issue Date entitled to receive payment of dividends subject only to those
      preferential rights of dividends granted to the Series A and, for purposes
      of
      these resolutions, shall mean any class or series of stock of the Company
      authorized after the Issue Date entitled to receive assets upon liquidation,
      dissolution or winding up of the affairs of the Company subject to only those
      preferential rights and preference granted to the Series A.

    

    Senior
      Stock
      . The
      term “Senior Stock” shall mean, for purposes of these resolutions, any class or
      series of stock of the Company authorized before the Issue Date of the Series
      A
      except for those preferential rights as granted herein but the right to receive
      dividends providing all dividends granted to the Series A shall have been paid
      or set aside to be paid, and, for purposes of these resolutions, shall mean
      any
      class or series of stock of the Company authorized after the Issue Date ranking
      equal to the Series A and the right to participate in any distribution upon
      liquidation, dissolution or winding up of the affairs of the Company except
      for
      those preferential rights granted to the Series A herein.

    

    
      	
              2.

            	
              Rights,
                Powers, and Preferences

            

    

    

    The
      Series A shall have the voting powers, preferences and relative, participating,
      optional and other special rights, qualifications, limitations and restrictions
      as follows:

    

    
      	
               

            	
              A.

            	
              Designation
                and Amount
                .
                Out of the Twenty Million (20,000,000) shares of the $.001 par value
                authorized preferred stock, Two Million (2,000,000) shares shall
                be
                designated as shares of “Series A.”

            

    

    

    
      	
               

            	
              B.

            	
              Rank
                .
                The Series A shall be senior to the Common Stock and any other series
                or
                class of the Company’s Preferred
                Stock.

            

    

    

    
      	
               

            	
              C.

            	
              Liquidation
                Rights
                .

            

    

    

    
      	
               

            	
              (i)

            	
              In
                the event of any liquidation, dissolution, or winding up of the Company,
                whether voluntary or involuntary, the holders of the Series A then
                outstanding shall be entitled to be paid out of the assets of the
                Company
                available for distribution to its shareholders, before any payment
                or
                declaration and setting apart for payment of any amount shall be
                made in
                respect of any outstanding capital stock of the Company, an amount
                equal
                to ($.001) per share, plus the Redemption provision (as defined below).
                Then all of the assets of the Company available to be distributed
                shall be
                distributed ratably to the holders of the Series A and then to the
                holders
                of other outstanding shares of capital stock of the Company. If upon
                any
                liquidation, dissolution, or winding up of the Company, whether voluntary
                or involuntary, the assets to be distributed to the holders of the
                Series
                A shall be insufficient to permit the payment to the holders thereof
                the
                full preferential amount as provided herein, then such available
                assets
                shall be distributed ratably to the holders of the Series
                A.

            

    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	
               

            	
              (ii)

            	
              None
                of the following events shall be treated as or deemed to be a liquidation
                hereunder:

            

    

    

    
      	
               

            	
              (a)

            	
              A
                merger, consolidation or reorganization of the
                Company;

            

    

    

    
      	
               

            	
              (b)

            	
              A
                sale or other transfer of all or substantially all of the Company's
                assets;

            

    

    

    
      	
               

            	
              (c)

            	
              A
                sale of 50% or more of the Company's capital stock then issued and
                outstanding;

            

    

    

    
      	
               

            	
              (d)

            	
              A
                purchase or redemption by the Company of stock of any class;
                or

            

    

    

    
      	
               

            	
              (e)

            	
              Payment
                of a dividend or distribution from funds legally available
                therefor.

            

    

    

    
      	
               

            	
              D.

            	
              Voting
                Rights
                .
                In all matters the Series A shall have the same voting rights as
                the
                Common Stock on a six to one (6:1) basis. If the Company effects
                a stock
                split which either increases or decreases the number of shares of
                Common
                Stock outstanding and entitled to vote, the voting rights of the
                Series A
                shall not be subject to adjustment unless specifically
                authorized.

            

    

    

    3.
            Dividends

    

    The
      holders of the Series A shall be entitled to receive Common Stock dividends
      when, as, if and in the amount declared by the directors of the Company to
      be
      paid in cash or in Market Value of the Company’s common stock.

    

    Without
      prior written consent of the majority of the holders of Series A, so long as
      any
      shares of Series A shall be outstanding, the Company shall not declare or pay
      on
      any Junior Stock any dividend whatsoever, whether in cash, property or
      otherwise, nor shall the Company make any distribution on any Junior Stock,
      nor
      shall any Junior Stock be purchased or redeemed by the Company or any of its
      subsidiaries of which it owns not less than 51% of the outstanding voting stock,
      nor shall any monies be paid or made available for a sinking fund for the
      purchase or redemption of any Junior Stock, unless all dividends to which the
      holders of Series A shall have been entitled for all previous dividend periods,
      if any, shall have been paid or declared and a sum of money sufficient for
      the
      payment thereof and the Redemption Price (as hereinafter defined) is set
      apart.

    

    
      	
              4.

            	
              Conversion

            

    

    

    The
      Series A shall have the following conversion rights (the “Conversion
      Rights”):

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	
               

            	
              A.

            	
              Holder's
                Optional Right to Convert
                .
                Each share of Series A shall be convertible, at the option of the
                holder(s), on the Conversion Basis (as set forth below) in effect
                at the
                time of conversion. Such right to convert shall commence as of the
                Issue
                Date and shall continue thereafter for a period of five years, such
                period
                ending on the fifth anniversary of the Issue Date. In the event that
                the
                holder(s) of the Series A elect to convert such shares into Common
                Stock,
                the holder(s) shall have sixty (60) days from the date of such notice
                in
                which to tender their shares of Series A to the
                Company.

            

    

    

    
      	
               

            	
              B.

            	
              Conversion
                Basis
                .
                Each share of Series A shall be convertible into six (6) shares of
                the
                Company’s Common Stock.

            

    

    

    
      	
               

            	
              C.

            	
              Mechanics
                of Conversion
                .
                Before any holder of Series A shall be entitled to convert the same
                into
                shares of Common Stock, such holder shall (i) give written notice
                to the
                Company, at the office of the Company or of its transfer agent for
                the
                Common Stock or the Preferred Stock, that he elects to convert the
                same
                and shall state therein the number of shares of Series A being converted;
                and (ii) surrender the certificate or certificates therefor, duly
                endorsed. Thereupon the Company shall promptly issue and deliver
                to such
                holder of Series A a certificate or certificates for the number of
                shares
                of Common Stock to which such holder shall be entitled. The conversion
                shall be deemed to have been made and the resulting shares of Common
                Stock
                shall be deemed to have been issued immediately prior to the close
                of
                business on the date of such notice and surrender of the shares of
                Series
                A.

            

    

    

    
      	
               

            	
              D.

            	
              Adjustments
                to the Conversion Basis.

            

    

    

    
      	
               

            	
              (i)

            	
              Stock
                Splits and Combinations
                .
                The Series A shall not be adjusted pursuant to any subdivision or
                combination of the Common Stock.

            

    

    

    
      	
               

            	
              (ii)

            	
              Reclassification,
                Exchange or Substitution
                .
                At any time after the Company first issues the Series A and while
                any of
                the shares of Series A remain outstanding, if the Common Stock issuable
                upon the conversion of the Series A shall be changed into the same
                or a
                different number of shares of any class or classes of stock, whether
                by
                capital reorganization, reclassification, or otherwise (other than
                a
                subdivision or combination of shares or stock dividend provided for
                above,
                or a reorganization, merger, consolidation, or sale of assets), then
                and
                in each such event the holder of each share of Series A shall have
                the
                right thereafter to convert such shares into the kind and amount
                of shares
                of stock and other securities and property receivable upon such
                reorganization, reclassification, or other change, by holders of
                the
                number of shares of Common Stock into which such shares of Series
                A might
                have been converted immediately prior to such reorganization,
                reclassification, or change, all subject to further adjustments as
                provided herein.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
               

            	
              (iii)

            	
              Reorganization,
                Mergers, Consolidations or Sales of Assets
                .
                At any time after the Company first issues the Series A and while
                any of
                such shares remain outstanding, if there shall be a capital reorganization
                of the Common Stock (other than a subdivision, combination,
                reclassification, or exchange of shares), or a merger or consolidation
                of
                the Company with or into another Company, or the sale of all or
                substantially all of the Company's assets to any other person, then
                as a
                part of such reorganization, merger, consolidation, or sale, provision
                shall be made so that the holders of the Series A thereafter shall
                be
                entitled to receive upon conversion of the Series A, the number of
                shares
                of stock or other securities or property of the Company, or of the
                successor Company resulting from such merger or consolidation or
                sale, to
                which a holder of Series A deliverable upon conversion would have
                been
                entitled on such capital reorganization, merger, consolidation, or
                sale.

            

    

     

    
      	
               

            	
              E.

            	
              Notices
                of Record Date
                .
                In the event of any reclassification or recapitalization of the capital
                stock of the Company, any merger or consolidation of the Company,
                or any
                transfer of all or substantially all of the assets of the Company
                to any
                other Company, entity, or person, or any voluntary or involuntary
                dissolution, liquidating, or winding up of the Company, the Company
                shall
                mail to each holder of Series A at least 30 days prior to the record
                date
                specified therein, a notice specifying the date on which any such
                reorganization, reclassification, transfer, consolidation, merger,
                dissolution, liquidation, or winding up is expected to become effective,
                and the time, if any is to be fixed, as to when the holders of record
                of
                Common Stock (or other securities) shall be entitled to exchange
                their
                shares of Common Stock (or other securities) for securities or other
                property deliverable upon such reorganization, reclassification,
                transfer,
                consolidation, merger, dissolution, liquidation, or winding
                up.

            

    

    

    
      	
               

            	
              F.

            	
              Fractional
                Shares
                .
                No fractional shares of Common Stock shall be issued upon conversion
                of
                the Series A. In lieu of any fractional shares to which the holder
                would
                otherwise be entitled, the Company shall pay cash equal to the product
                of
                such fraction multiplied by the fair market value of one share of
                the
                Company's Common Stock on the date of conversion, as determined in
                good
                faith by the Company’s directors.

            

    

    

    
      	
               

            	
              G.

            	
              Reservation
                of Stock Issuable Upon Conversion
                .
                The Company shall reserve and keep available out of its authorized
                but
                unissued shares of Common Stock, solely for the purpose of effecting
                the
                conversion of the shares of the Series A, a number of its shares
                of Common
                Stock as shall from time to time be sufficient to effect the conversion
                of
                all outstanding shares of the Series
                A.

            

    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    5.
            Protective
      Provisions

    

    Notwithstanding
      anything contained herein to the contrary, so long as any of the Series A shall
      be outstanding, the Company shall not without first obtaining the approval
      (by
      vote or written consent, as provided by law) of the holders of at least
      two-thirds of the total number of shares of Series A outstanding:

    

    
      	
               

            	
              A.

            	
              Alter
                or change the rights, preferences or privileges of the Series A by
                way of
                reclassification, merger, consolidation or otherwise, so as to adversely
                affect in any manner the voting rights including number of votes
                presently
                allowed or the conversion basis by which the shares of Series A are
                presently converted into shares of Common
                Stock.

            

    

    

    
      	
               

            	
              B.

            	
              Increase
                the authorized number of share of Series
                A.

            

    

    

    
      	
               

            	
              C.

            	
              Create
                any new class of shares having preferences over or being on a parity
                with
                the Series A as to dividends or assets, unless the purpose of creation
                of
                such class is, and the proceeds to be derived from the sale and issuance
                thereof are to be used for, the retirement of all Series A then
                outstanding.

            

    

    

    
      	
               

            	
              D.

            	
              Repurchase
                any of the Company's Common Stock.

            

    

    

    
      	
               

            	
              E.

            	
              Merge
                or consolidate with any other Company, except into or with a wholly-owned
                subsidiary of the Company with the requisite shareholder
                approval.

            

    

    

    
      	
               

            	
              F.

            	
              Sell,
                convey or otherwise dispose of, or create or incur any mortgage,
                lien,
                charge or encumbrance on or security interest in or pledge of, or
                sell and
                leaseback, all or substantially all of the property or business of
                the
                Company.

            

    

    

    
      	
               

            	
              G.

            	
              Incur,
                assume or guarantee any indebtedness (other than such as may be
                represented by the obligation to pay rent under leases) maturing
                more than
                18 months after the date on which it is incurred, assumed or guaranteed
                by
                the Company, except purchase money obligations, obligations assumed
                as
                part of the price of property purchased, or the extension, renewal
                or
                refunding of any thereof.

            

    

    

    6.
            Redemption

    

    Subject
      to the applicable provisions of Delaware law, the Company, at the option of
      its
      directors, may at any time or from time to time redeem the whole or any part
      of
      the outstanding Series A. Upon redemption the Company shall pay for each share
      redeemed the amount of $2.00 per share, payable in cash, plus a premium to
      compensate the original purchaser(s) for the investment risk and cost of capital
      equal to the greater of (a) $2.00 per share, or (b) an amount per share equal
      to
      fifty percent (50%) of the market capitalization of the Company on the date
      of
      notice of such redemption divided by 2,000,000 (the “Redemption Premium”), the
      redemption amount and the Redemption Premium hereinafter being referred to
      as
      the “Redemption Price.” Such redemption shall be on an all-or-nothing
      basis.

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    At
      least
      thirty (30) days previous notice by mail, postage prepaid, shall be given to
      the
      holders of record of the Series A to be redeemed, such notice to be addressed
      to
      each such shareholder at the address of such holder appearing on the books
      of
      the Company or given to such holder to the Company for the purpose of notice,
      or
      if no such address appears or is given, at the place where the principal office
      of the Company is located. Such notice shall state the date fixed for redemption
      and the redemption price, and shall call upon the holder to surrender to the
      Company on said date at the place designated in the notice such holder's
      certificate or certificates represen-ting the shares to be redeemed. On or
      after
      the date fixed for redemption and stated in such notice, each holder of Series
      A
      called for redemption shall surrender the certificate evidencing such shares
      to
      the Company at the place designated in such notice and shall thereupon be
      entitled to receive payment of the redemption price. If less than all the shares
      represented by any such surrendered certificate are redeemed, a new certificate
      shall be issued representing the unredeemed shares. If such notice of redemption
      shall have been duly given, and if on the date fixed for redemption funds
      necessary for the redemption shall be available therefore, notwithstanding
      that
      the certificates evidencing any Series A called for redemption shall not have
      been surrendered, the divid-ends with respect to the shares so called for
      redemption shall forthwith after such date cease and determine, except only
      the
      right of the holders to receive the redemption price without interest upon
      surrender of their certificates therefore.

    

    If,
      on or
      prior to any date fixed for redemption or Series A, the Company deposits, with
      any bank or trust company as a trust fund, the number of shares of Common Stock
      of a sum sufficient to redeem, on the date fixed for redemption thereof, the
      shares called for redemption, with irrevocable instructions and authority to
      the
      bank or trust company to give the notice of redemption thereof (or to complete
      the giving of such notice if theretofore commenced) and to pay, or deliver,
      on
      or after the date fixed for redemption or prior thereto, the redemption price
      of
      the shares to their respective holders upon the surrender of their share
      certificates, then from and after the date of the deposit (although prior to
      the
      date fixed for redemption), the shares so called shall be redeemed and any
      dividends on those shares shall cease to accrue after the date fixed for
      redemption. The deposit shall constitute full payment of the shares to their
      holders and from and after the date of the deposit the shares shall no longer
      be
      outstanding and the holders thereof shall cease to be shareholders with respect
      to such shares, and shall have no rights with respect thereto except the right
      to receive from the bank or trust company payment of the redemption price of
      the
      shares without interest, upon the surrender of their certificates therefore.
      Any
      interest accrued on any funds so deposited shall be the property of, and paid
      to, the Company. If the holders of Series A so called for redemption shall
      not,
      at the end of six years from the date fixed for redemption thereof, have claimed
      any funds so deposited, such bank or trust company shall thereupon pay over
      to
      the Company such unclaimed funds, and such bank or trust company shall
      thereafter be relieved of all responsibility in respect thereof to such holders
      and such holders shall look only to the Company for payment of the redemption
      price.

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    7.
            Reissuance

    

    No
      share
      or shares of Series A acquired by the Company by reason of conversion or
      otherwise shall be reissued as Series A, and all such shares thereafter shall
      be
      returned to the status of undesignated and unissued shares of Preferred Stock
      of
      the Company.

    

    
      	
              8.

            	
              Headings
                or Subdivisions

            

    

    

    The
      heading of the various subdivisions hereof are for convenience of reference
      only
      and shall not affect the interpretation of any of the provisions
      hereto.

    

    
      	
              9.

            	
              Severability
                of Provisions

            

    

    

    If
      any
      right, preference or limitation of the Series A set forth in this resolution
      (as
      such resolution may be amended from time to time) is invalid, unlawful or
      incapable of being enforced by reason of any rule of law or public policy,
      all
      other rights, preferences and limitations set forth in this resolution (as
      so
      amended) which can be given effect without the invalid, unlawful or
      unenforceable right, preference or limitation shall, nevertheless, remain in
      full force and effect, and no right, preference or limitation herein set forth
      shall be deemed dependent upon any other such right, preference or limitation
      unless so expressed herein.

    

    10.
            Status
      of Reacquired Stock

    

    Shares
      of
      Series A which have been issued and reacquired in any manner shall, upon
      compliance with any applicable provisions of Delaware law, have the status
      of
      authorized and unissued shares of Preferred Stock may be redesignated and
      reissued in any series or class.

    

    IN
      WITNESS WHEREOF, the undersigned officers of Mason Hill Holdings, Inc., a
      Delaware corporation, did hereby execute this Certificate effective this 26th
      day of May, 2006.

    

    

    /s/
      Geoffrey Eiten

    Geoffrey
      Eiten

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}]]